Bridgeway Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-201,600
| Closed | -$35K | – | 1502 |
|
|
2022
Q3 | $35K | Buy |
201,600
+75,000
| +59% | +$13K | ﹤0.01% | 1366 |
|
|
2022
Q2 | $76K | Sell |
126,600
-160,000
| -56% | -$96.1K | ﹤0.01% | 1253 |
|
|
2022
Q1 | $378K | Hold |
286,600
| – | – | 0.01% | 1014 |
|
|
2021
Q4 | $748K | Buy |
286,600
+81,000
| +39% | +$211K | 0.01% | 859 |
|
|
2021
Q3 | $639K | Buy |
205,600
+117,000
| +132% | +$364K | 0.01% | 960 |
|
|
2021
Q2 | $330K | Sell |
88,600
-24,000
| -21% | -$89.4K | 0.01% | 1190 |
|
|
2021
Q1 | $390K | Sell |
112,600
-15,000
| -12% | -$52K | 0.01% | 1165 |
|
|
2020
Q4 | $429K | Sell |
127,600
-25,000
| -16% | -$84.1K | 0.01% | 1004 |
|
|
2020
Q3 | $536K | Hold |
152,600
| – | – | 0.01% | 862 |
|
|
2020
Q2 | $702K | Sell |
152,600
-30,900
| -17% | -$142K | 0.01% | 764 |
|
|
2020
Q1 | $607K | Buy |
183,500
+9,100
| +5% | +$30.1K | 0.01% | 699 |
|
|
2019
Q4 | $1.07M | Buy |
+174,400
| New | +$1.07M | 0.01% | 722 |
|